Adjunctive Semaglutide in Patients Undergoing Intragastric Balloon for Weight Loss: 12-Month Prospective Comparative Study - Takeaways - MDSpire

Adjunctive Semaglutide in Patients Undergoing Intragastric Balloon for Weight Loss: 12-Month Prospective Comparative Study

  • By

  • Khaled E. Barakat

  • Doaa K. Abuhasan

  • Mohamed F. Asal

  • Ahmed Adham R. Elsayed

  • Mohamed R. Mahmoud

  • Madeline Guy

  • Rama Safadi

  • Marc D. Basson

  • November 10, 2025

  • 0 min

Share

  • 1

    Obesity is a global health crisis, with rates doubling in the past 35 years, necessitating effective management strategies.

  • 2

    Intragastric balloons (IGBs) provide a less invasive weight loss option, but their efficacy combined with semaglutide remains unclear.

  • 3

    Semaglutide is an effective GLP-1 receptor agonist approved for weight management in adults with obesity or overweight.

  • 4

    This study randomized participants to receive either IGB alone or IGB with semaglutide to evaluate combined weight loss efficacy.

  • 5

    The semaglutide dosing regimen was designed to optimize weight loss effects while minimizing adverse effects during IGB placement.

Original Source(s)

Adjunctive Semaglutide in Patients Undergoing Intragastric Balloon for Weight Loss: 12-Month Prospective Comparative Study

  • by Khaled E. Barakat, Doaa K. Abuhasan, Mohamed F. Asal, Ahmed Adham R. Elsayed, Mohamed R. Mahmoud, Madeline Guy, Rama Safadi, Marc D. Basson

  • November 10, 2025

Related Content

Semaglutide Linked to NAION Risk

A retrospective database study found a low absolute incidence but higher relative hazard of ischemic optic neuropathy following semaglutide initiation.

Correction: Link Between Zinc Deficiency and Healthcare Resource Use in Patients Receiving Metabolic and Bariatric Surgery: A Retrospective Cohort Analysis

Venous Thromboembolism and Bleeding Risk in a Population with Obesity Hospitalized for Surgery and Receiving Enoxaparin for Thromboprophylaxis